If BTK inhibition is of clinical benefit in severe COVID-19, as is supported by our data, it raises the question of which BTK inhibitor would be optimal in this clinical setting given the association of COVID-19 with arrythmias and other serious systemic sequelae of the inflammatory process. This evidence concerns the gene BTK and cardiac arrhythmia.